Kathir personal page - To The Moon

Kathir

Kathir

No personal profile

69Follow

7Followers

0Topic

0Badge

2021-08-05

Wow

Wall Street closes mixed, S&P 500 ends off record high

2021-08-05

Wow

Toplines After Hours US Market on Wednesday

2021-09-19

Ohhh

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-08-05

Wow

'Apex Legends' creator EA forecasts quarterly sales above estimates

2021-09-19

Interesting

Virgin Galactic stock dropped 3.4% in premarket trading

2021-08-16

Wow does that mean the market is going down now?

@KennyLSJ:$NIO Inc.(NIO)$I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities and user experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou

01-15

Let's gooo!!! 2 more days!!

01-14

Let's jeep it going! The end is near

01-12

An easy way to learn and capitalise on the oppurtunity

01-11

A fun experience taking oart in thsi challenge

01-29

$Microsoft(MSFT)$ have a good stronghold in the market

01-15

Think n tell me your views

01-14

huat all!

@TigerEvents:🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅

01-14

That's the way

@Retire Smart:Huat huat all the way

01-13

Come and enjoy free rewards

01-11

Tiger revenue increasing as nyse charts a new high

01-11

Great ariticle, would you like to share it?

@Pepeflabs:Valod post vaild post

01-11

Great ariticle, would you like to share it?

@MillionaireTiger:Outperforming the Market by 140% in the Past Year: Is CRWD the Top Cybersecurity Stocks?

01-10

Great ariticle, would you like to share it?

@TigerEvents:🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3584711357780922","uuid":"3584711357780922","gmtCreate":1626796037621,"gmtModify":1628154671195,"name":"Kathir","pinyin":"kathir","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":69,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":268259076993168,"gmtCreate":1706510802436,"gmtModify":1706510810633,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$&nbsp;</a> have a good stronghold in the market&nbsp;","listText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$&nbsp;</a> have a good stronghold in the market&nbsp;","text":"$Microsoft(MSFT)$ have a good stronghold in the market","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/268259076993168","isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263164963803216,"gmtCreate":1705283421461,"gmtModify":1705283426272,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Think n tell me your views","listText":"Think n tell me your views","text":"Think n tell me your views","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263164963803216","isVote":1,"tweetType":1,"viewCount":546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263020299944016,"gmtCreate":1705248103136,"gmtModify":1705248107252,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Let's gooo!!! 2 more days!!","listText":"Let's gooo!!! 2 more days!!","text":"Let's gooo!!! 2 more days!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263020299944016","isVote":1,"tweetType":1,"viewCount":710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019307909208,"gmtCreate":1705247884919,"gmtModify":1705247888950,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"huat all!","listText":"huat all!","text":"huat all!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019307909208","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019272527984,"gmtCreate":1705247860968,"gmtModify":1705247865266,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"That's the way&nbsp;","listText":"That's the way&nbsp;","text":"That's the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019272527984","repostId":"263019199787224","repostType":1,"repost":{"id":263019199787224,"gmtCreate":1705247703017,"gmtModify":1705247706445,"author":{"id":"3584008590338956","authorId":"3584008590338956","name":"Retire Smart","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584008590338956","authorIdStr":"3584008590338956"},"themes":[],"htmlText":"Huat huat all the way","listText":"Huat huat all the way","text":"Huat huat all the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019199787224","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019712897248,"gmtCreate":1705247842474,"gmtModify":1705247847322,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Let's jeep it going! The end is near","listText":"Let's jeep it going! The end is near","text":"Let's jeep it going! The end is near","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019712897248","isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":262455724106040,"gmtCreate":1705110155270,"gmtModify":1705110159916,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Come and enjoy free rewards","listText":"Come and enjoy free rewards","text":"Come and enjoy free rewards","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/262455724106040","isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":262114045251600,"gmtCreate":1705027431924,"gmtModify":1705027436348,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"An easy way to learn and capitalise on the oppurtunity","listText":"An easy way to learn and capitalise on the oppurtunity","text":"An easy way to learn and capitalise on the oppurtunity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/262114045251600","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261879256092832,"gmtCreate":1704945822447,"gmtModify":1704945826717,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Tiger revenue increasing as nyse charts a new high","listText":"Tiger revenue increasing as nyse charts a new high","text":"Tiger revenue increasing as nyse charts a new high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261879256092832","isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261879472197912,"gmtCreate":1704945782180,"gmtModify":1704945786601,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"A fun experience taking oart in thsi challenge","listText":"A fun experience taking oart in thsi challenge","text":"A fun experience taking oart in thsi challenge","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261879472197912","isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261875544965352,"gmtCreate":1704944947207,"gmtModify":1704944950571,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261875544965352","repostId":"261578332447000","repostType":1,"repost":{"id":261578332447000,"gmtCreate":1704872261733,"gmtModify":1704872265634,"author":{"id":"3573162818118967","authorId":"3573162818118967","name":"Pepeflabs","avatar":"https://static.tigerbbs.com/bb2ce4a85b6af8ab6f45834a991797c6","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3573162818118967","authorIdStr":"3573162818118967"},"themes":[],"htmlText":"Valod post vaild post","listText":"Valod post vaild post","text":"Valod post vaild post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261578332447000","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261875129536696,"gmtCreate":1704944841127,"gmtModify":1704944844913,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261875129536696","repostId":"261217496645664","repostType":1,"repost":{"id":261217496645664,"gmtCreate":1704801733495,"gmtModify":1705406662474,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/dc558bf32e48ad6ed6d057026ef55af7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667618821228","authorIdStr":"3527667618821228"},"themes":[],"title":"Outperforming the Market by 140% in the Past Year: Is CRWD the Top Cybersecurity Stocks?","htmlText":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to <a href=\"https://ttm.financial/U/3586385042163137\">@Arshadrzk</a> for achieving a profit of over $1,000+ through the purchase of <a href=\"https://ttm.financial/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a> common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","listText":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to <a href=\"https://ttm.financial/U/3586385042163137\">@Arshadrzk</a> for achieving a profit of over $1,000+ through the purchase of <a href=\"https://ttm.financial/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a> common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","text":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the $NASDAQ(.IXIC)$ by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to @Arshadrzk for achieving a profit of over $1,000+ through the purchase of $CrowdStrike Holdings, Inc.(CRWD)$ common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","images":[{"img":"https://community-static.tradeup.com/news/2e55c5f5093e77e70ca0854e08a6be13","width":"1080","height":"1080"},{"img":"https://community-static.tradeup.com/news/a0307398b8a41055d8c9bb416c79f2a1","width":"1772","height":"771"},{"img":"https://community-static.tradeup.com/news/788ec0cd0e85522183278db2ff1ab0d3","width":"1440","height":"1080"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261217496645664","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261591377039416,"gmtCreate":1704875428746,"gmtModify":1704875432099,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261591377039416","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887119446,"gmtCreate":1632006704385,"gmtModify":1676530683652,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887119446","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887119368,"gmtCreate":1632006597654,"gmtModify":1676530683628,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887119368","repostId":"1136416859","repostType":2,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830707769,"gmtCreate":1629096328351,"gmtModify":1676529928257,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Wow does that mean the market is going down now?","listText":"Wow does that mean the market is going down now?","text":"Wow does that mean the market is going down now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/830707769","repostId":"895207908","repostType":1,"repost":{"id":895207908,"gmtCreate":1628744306004,"gmtModify":1676529840280,"author":{"id":"3568358014488959","authorId":"3568358014488959","name":"KennyLSJ","avatar":"https://static.tigerbbs.com/6b5ebe536d7e7f6f56f6fcaeab8f5eda","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3568358014488959","authorIdStr":"3568358014488959"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities&nbsp;and user&nbsp;experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities&nbsp;and user&nbsp;experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","text":"$NIO Inc.(NIO)$I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities and user experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895207908","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890252138,"gmtCreate":1628121346024,"gmtModify":1703501484259,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890252138","repostId":"2157483930","repostType":4,"isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890227802,"gmtCreate":1628121092106,"gmtModify":1703501474374,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890227802","repostId":"2157488120","repostType":4,"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890221467,"gmtCreate":1628120861559,"gmtModify":1703501470084,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584711357780922","authorIdStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890221467","repostId":"1179402387","repostType":4,"repost":{"id":"1179402387","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628120638,"share":"https://ttm.financial/m/news/1179402387?lang=&edition=fundamental","pubTime":"2021-08-05 07:43","market":"us","language":"en","title":"Toplines After Hours US Market on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1179402387","media":"Tiger Newspress","summary":"Futures contracts tied to the major U.S. equity indexes were little changed at the start of the over","content":"<p>Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.</p>\n<p>At 7:30&nbsp;p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&amp;P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/15029cdb3b40554099587488dcc610a7\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Stocks making biggest moves after hours: Etsy, Electronic Arts, Roku &amp; more</b></p>\n<p><a href=\"https://laohu8.com/S/FSLY\">Fastly, Inc.</a> (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.</p>\n<p>Ping Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.</p>\n<p>Etsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.</p>\n<p>PetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.</p>\n<p>Lemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.</p>\n<p><a href=\"https://laohu8.com/S/MAXR\">Maxar Technologies Ltd.</a> (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.</p>\n<p>Roku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.</p>\n<p>Western Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.</p>\n<p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.</p>\n<p>Uber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.</p>\n<p>Electronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines After Hours US Market on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines After Hours US Market on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 07:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.</p>\n<p>At 7:30&nbsp;p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&amp;P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/15029cdb3b40554099587488dcc610a7\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Stocks making biggest moves after hours: Etsy, Electronic Arts, Roku &amp; more</b></p>\n<p><a href=\"https://laohu8.com/S/FSLY\">Fastly, Inc.</a> (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.</p>\n<p>Ping Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.</p>\n<p>Etsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.</p>\n<p>PetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.</p>\n<p>Lemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.</p>\n<p><a href=\"https://laohu8.com/S/MAXR\">Maxar Technologies Ltd.</a> (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.</p>\n<p>Roku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.</p>\n<p>Western Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.</p>\n<p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.</p>\n<p>Uber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.</p>\n<p>Electronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EA":"艺电","WU":"西联汇款",".DJI":"道琼斯","PING":"Ping Identity Holding","MELI":"MercadoLibre","PETQ":"Petiq Inc.","ROKU":"Roku Inc",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","BKNG":"Booking Holdings","FSLY":"Fastly, Inc.","UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179402387","content_text":"Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.\nAt 7:30 p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.\n\nStocks making biggest moves after hours: Etsy, Electronic Arts, Roku & more\nFastly, Inc. (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.\nPing Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.\nEtsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.\nPetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.\nLemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.\nMaxar Technologies Ltd. (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.\nRoku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.\nWestern Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.\nMercadoLibre (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.\nUber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.\nElectronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.\nBooking Holdings (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":890252138,"gmtCreate":1628121346024,"gmtModify":1703501484259,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890252138","repostId":"2157483930","repostType":4,"repost":{"id":"2157483930","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628118320,"share":"https://ttm.financial/m/news/2157483930?lang=&edition=fundamental","pubTime":"2021-08-05 07:05","market":"us","language":"en","title":"Wall Street closes mixed, S&P 500 ends off record high","url":"https://stock-news.laohu8.com/highlight/detail?id=2157483930","media":"Reuters","summary":"GM slides despite posting quarterly profit\n\n\nPrivate payrolls growth slows as labor shortages linger","content":"<ul>\n <li>GM slides despite posting quarterly profit</li>\n</ul>\n<ul>\n <li>Private payrolls growth slows as labor shortages linger</li>\n</ul>\n<ul>\n <li>Netflix, <a href=\"https://laohu8.com/S/FB\">Facebook</a> outperform</li>\n</ul>\n<ul>\n <li>Indexes: Dow off 0.92%, S&amp;P down 0.46%, Nasdaq up 0.13%</li>\n</ul>\n<p>Aug 4 (Reuters) - U.S. stocks closed mostly lower on Wednesday, with the S&amp;P 500 falling from a record high after data signaled a slowdown in jobs growth in July, and <a href=\"https://laohu8.com/S/GM\">General Motors</a> tracked its worst day since early March.</p>\n<p>GM's shares slumped 8.9%, underscoring the uncertainty facing global automakers at a time of technological and economic disruption. Shares of rival <a href=\"https://laohu8.com/S/F\">Ford</a> fell 5.0%.</p>\n<p>Nine of the 11 S&amp;P indexes were lower, with industrials&nbsp;and energy&nbsp;both slipping, as data showed U.S. private payrolls increased far less than expected in July, likely constrained by shortages of workers and raw materials.</p>\n<p>The blue-chip Dow, heavily weighted toward economically-sensitive stocks, also declined.</p>\n<p>The technology-heavy Nasdaq&nbsp;bucked the trend after another report showed a measure of U.S. services industry activity jumped to a record high last month, suggesting a broader economic rebound was still on track.</p>\n<p>\"The ADP employment report this morning (is a) big miss ... has people really locked in on tomorrow's initial claims and then Friday's non-farm payrolls report,\" said Ross Mayfield, investment strategist at Baird in Louisville, Kentucky. \"To me that’s a big driver (of the market today).\"</p>\n<p>\"Broadly, the continued evolution of COVID-19, the Delta variant over the recent weeks and months kind of re-rating of the growth outlook\" has the market coming to terms with what it means for the reflation trade, and what it means to the bond market, Mayfield said.</p>\n<p>After six straight month of gains, the benchmark S&amp;P 500&nbsp;has struggled to rise in August over concerns about the pace of growth as the economy rebounded from the depths of the COVID-19-driven recession, and fears of higher inflation overshadowed a stellar corporate earnings season.</p>\n<p>Federal Reserve Vice Chair Richard Clarida said on Wednesday the central bank should be in the position to begin raising interest rates in 2023.</p>\n<p>Still, tech and tech-adjacent stocks such as <a href=\"https://laohu8.com/S/NFLX\">Netflix</a> and <a href=\"https://laohu8.com/S/FB\">Facebook</a>, which tend to perform better when interest rates are lower, outperformed the broader market.</p>\n<p>Focus now turns to the Labor Department's monthly jobs report on Friday.</p>\n<p>The Dow Jones Industrial Average fell 323.73 points, or 0.92%, to 34,792.67, the S&amp;P 500&nbsp;lost 20.49 points, or 0.46%, to 4,402.66 and the Nasdaq Composite added 19.24 points, or 0.13%, to 14,780.53.</p>\n<p>In earnings-related moves, BorgWarner Inc fell even as it beat profit expectations on strong consumer demand for new vehicles, while Kraft Heinz Co tumbled after warning of margin pressure from higher prices of ingredients.</p>\n<p><a href=\"https://laohu8.com/S/HOOD\">Robinhood Markets, Inc.</a> jumped 50.4% as interest from star fund manager Cathie Wood and small-time traders set up the stock for a fourth session of gains after its underwhelming market debut last week.</p>\n<p>Volume on U.S. exchanges was 9.78 billion shares, compared with the 9.71 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.02-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored decliners.</p>\n<p>The <a href=\"https://laohu8.com/S/.SPX\">S&amp;P 500</a> posted 67 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 93 new highs and 107 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street closes mixed, S&P 500 ends off record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street closes mixed, S&P 500 ends off record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-05 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>GM slides despite posting quarterly profit</li>\n</ul>\n<ul>\n <li>Private payrolls growth slows as labor shortages linger</li>\n</ul>\n<ul>\n <li>Netflix, <a href=\"https://laohu8.com/S/FB\">Facebook</a> outperform</li>\n</ul>\n<ul>\n <li>Indexes: Dow off 0.92%, S&amp;P down 0.46%, Nasdaq up 0.13%</li>\n</ul>\n<p>Aug 4 (Reuters) - U.S. stocks closed mostly lower on Wednesday, with the S&amp;P 500 falling from a record high after data signaled a slowdown in jobs growth in July, and <a href=\"https://laohu8.com/S/GM\">General Motors</a> tracked its worst day since early March.</p>\n<p>GM's shares slumped 8.9%, underscoring the uncertainty facing global automakers at a time of technological and economic disruption. Shares of rival <a href=\"https://laohu8.com/S/F\">Ford</a> fell 5.0%.</p>\n<p>Nine of the 11 S&amp;P indexes were lower, with industrials&nbsp;and energy&nbsp;both slipping, as data showed U.S. private payrolls increased far less than expected in July, likely constrained by shortages of workers and raw materials.</p>\n<p>The blue-chip Dow, heavily weighted toward economically-sensitive stocks, also declined.</p>\n<p>The technology-heavy Nasdaq&nbsp;bucked the trend after another report showed a measure of U.S. services industry activity jumped to a record high last month, suggesting a broader economic rebound was still on track.</p>\n<p>\"The ADP employment report this morning (is a) big miss ... has people really locked in on tomorrow's initial claims and then Friday's non-farm payrolls report,\" said Ross Mayfield, investment strategist at Baird in Louisville, Kentucky. \"To me that’s a big driver (of the market today).\"</p>\n<p>\"Broadly, the continued evolution of COVID-19, the Delta variant over the recent weeks and months kind of re-rating of the growth outlook\" has the market coming to terms with what it means for the reflation trade, and what it means to the bond market, Mayfield said.</p>\n<p>After six straight month of gains, the benchmark S&amp;P 500&nbsp;has struggled to rise in August over concerns about the pace of growth as the economy rebounded from the depths of the COVID-19-driven recession, and fears of higher inflation overshadowed a stellar corporate earnings season.</p>\n<p>Federal Reserve Vice Chair Richard Clarida said on Wednesday the central bank should be in the position to begin raising interest rates in 2023.</p>\n<p>Still, tech and tech-adjacent stocks such as <a href=\"https://laohu8.com/S/NFLX\">Netflix</a> and <a href=\"https://laohu8.com/S/FB\">Facebook</a>, which tend to perform better when interest rates are lower, outperformed the broader market.</p>\n<p>Focus now turns to the Labor Department's monthly jobs report on Friday.</p>\n<p>The Dow Jones Industrial Average fell 323.73 points, or 0.92%, to 34,792.67, the S&amp;P 500&nbsp;lost 20.49 points, or 0.46%, to 4,402.66 and the Nasdaq Composite added 19.24 points, or 0.13%, to 14,780.53.</p>\n<p>In earnings-related moves, BorgWarner Inc fell even as it beat profit expectations on strong consumer demand for new vehicles, while Kraft Heinz Co tumbled after warning of margin pressure from higher prices of ingredients.</p>\n<p><a href=\"https://laohu8.com/S/HOOD\">Robinhood Markets, Inc.</a> jumped 50.4% as interest from star fund manager Cathie Wood and small-time traders set up the stock for a fourth session of gains after its underwhelming market debut last week.</p>\n<p>Volume on U.S. exchanges was 9.78 billion shares, compared with the 9.71 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.02-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored decliners.</p>\n<p>The <a href=\"https://laohu8.com/S/.SPX\">S&amp;P 500</a> posted 67 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 93 new highs and 107 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BWA":"博格华纳","F":"福特汽车","KHC":"卡夫亨氏","NFLX":"奈飞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157483930","content_text":"GM slides despite posting quarterly profit\n\n\nPrivate payrolls growth slows as labor shortages linger\n\n\nNetflix, Facebook outperform\n\n\nIndexes: Dow off 0.92%, S&P down 0.46%, Nasdaq up 0.13%\n\nAug 4 (Reuters) - U.S. stocks closed mostly lower on Wednesday, with the S&P 500 falling from a record high after data signaled a slowdown in jobs growth in July, and General Motors tracked its worst day since early March.\nGM's shares slumped 8.9%, underscoring the uncertainty facing global automakers at a time of technological and economic disruption. Shares of rival Ford fell 5.0%.\nNine of the 11 S&P indexes were lower, with industrials and energy both slipping, as data showed U.S. private payrolls increased far less than expected in July, likely constrained by shortages of workers and raw materials.\nThe blue-chip Dow, heavily weighted toward economically-sensitive stocks, also declined.\nThe technology-heavy Nasdaq bucked the trend after another report showed a measure of U.S. services industry activity jumped to a record high last month, suggesting a broader economic rebound was still on track.\n\"The ADP employment report this morning (is a) big miss ... has people really locked in on tomorrow's initial claims and then Friday's non-farm payrolls report,\" said Ross Mayfield, investment strategist at Baird in Louisville, Kentucky. \"To me that’s a big driver (of the market today).\"\n\"Broadly, the continued evolution of COVID-19, the Delta variant over the recent weeks and months kind of re-rating of the growth outlook\" has the market coming to terms with what it means for the reflation trade, and what it means to the bond market, Mayfield said.\nAfter six straight month of gains, the benchmark S&P 500 has struggled to rise in August over concerns about the pace of growth as the economy rebounded from the depths of the COVID-19-driven recession, and fears of higher inflation overshadowed a stellar corporate earnings season.\nFederal Reserve Vice Chair Richard Clarida said on Wednesday the central bank should be in the position to begin raising interest rates in 2023.\nStill, tech and tech-adjacent stocks such as Netflix and Facebook, which tend to perform better when interest rates are lower, outperformed the broader market.\nFocus now turns to the Labor Department's monthly jobs report on Friday.\nThe Dow Jones Industrial Average fell 323.73 points, or 0.92%, to 34,792.67, the S&P 500 lost 20.49 points, or 0.46%, to 4,402.66 and the Nasdaq Composite added 19.24 points, or 0.13%, to 14,780.53.\nIn earnings-related moves, BorgWarner Inc fell even as it beat profit expectations on strong consumer demand for new vehicles, while Kraft Heinz Co tumbled after warning of margin pressure from higher prices of ingredients.\nRobinhood Markets, Inc. jumped 50.4% as interest from star fund manager Cathie Wood and small-time traders set up the stock for a fourth session of gains after its underwhelming market debut last week.\nVolume on U.S. exchanges was 9.78 billion shares, compared with the 9.71 billion average for the full session over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.02-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored decliners.\nThe S&P 500 posted 67 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 93 new highs and 107 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890221467,"gmtCreate":1628120861559,"gmtModify":1703501470084,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890221467","repostId":"1179402387","repostType":4,"repost":{"id":"1179402387","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628120638,"share":"https://ttm.financial/m/news/1179402387?lang=&edition=fundamental","pubTime":"2021-08-05 07:43","market":"us","language":"en","title":"Toplines After Hours US Market on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1179402387","media":"Tiger Newspress","summary":"Futures contracts tied to the major U.S. equity indexes were little changed at the start of the over","content":"<p>Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.</p>\n<p>At 7:30&nbsp;p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&amp;P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/15029cdb3b40554099587488dcc610a7\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Stocks making biggest moves after hours: Etsy, Electronic Arts, Roku &amp; more</b></p>\n<p><a href=\"https://laohu8.com/S/FSLY\">Fastly, Inc.</a> (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.</p>\n<p>Ping Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.</p>\n<p>Etsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.</p>\n<p>PetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.</p>\n<p>Lemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.</p>\n<p><a href=\"https://laohu8.com/S/MAXR\">Maxar Technologies Ltd.</a> (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.</p>\n<p>Roku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.</p>\n<p>Western Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.</p>\n<p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.</p>\n<p>Uber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.</p>\n<p>Electronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines After Hours US Market on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines After Hours US Market on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 07:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.</p>\n<p>At 7:30&nbsp;p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&amp;P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/15029cdb3b40554099587488dcc610a7\" tg-width=\"1080\" tg-height=\"384\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Stocks making biggest moves after hours: Etsy, Electronic Arts, Roku &amp; more</b></p>\n<p><a href=\"https://laohu8.com/S/FSLY\">Fastly, Inc.</a> (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.</p>\n<p>Ping Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.</p>\n<p>Etsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.</p>\n<p>PetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.</p>\n<p>Lemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.</p>\n<p><a href=\"https://laohu8.com/S/MAXR\">Maxar Technologies Ltd.</a> (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.</p>\n<p>Roku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.</p>\n<p>Western Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.</p>\n<p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.</p>\n<p>Uber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.</p>\n<p>Electronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.</p>\n<p><a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EA":"艺电","WU":"西联汇款",".DJI":"道琼斯","PING":"Ping Identity Holding","MELI":"MercadoLibre","PETQ":"Petiq Inc.","ROKU":"Roku Inc",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","BKNG":"Booking Holdings","FSLY":"Fastly, Inc.","UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179402387","content_text":"Futures contracts tied to the major U.S. equity indexes were little changed at the start of the overnight session Wednesday evening as Wall Street looked to improve upon a mixed week.\nAt 7:30 p.m. ET, Dow e-minis were up 19 points, or 0.05%, S&P 500 e-minis were up 2.25 points, or 0.05%, and Nasdaq 100 e-minis were down 7.50 points, or 0.05%.\n\nStocks making biggest moves after hours: Etsy, Electronic Arts, Roku & more\nFastly, Inc. (NYSE: FSLY)19.3% LOWER; reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $85 million versus the consensus estimate of $85.73 million. Fastly, Inc. sees Q3 2021 EPS of ($0.21)-($0.18), versus the consensus of ($0.09). Fastly, Inc. sees Q3 2021 revenue of $82-85 million, versus the consensus of $98.02 million. Fastly, Inc. sees FY2021 EPS of ($0.65)-($0.57), versus the consensus of ($0.43). Fastly, Inc. sees FY2021 revenue of $340-350 million, versus the consensus of $382.34 million.\nPing Identity (NYSE: PING) 13.2% HIGHER; reported Q2 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $66.09 million. Ping Identity sees Q3 2021 revenue of $65-70 million, versus the consensus of $65.1 million. Ping Identity sees FY2021 revenue of $278-285 million, versus the consensus of $269.3 million.\nEtsy (NASDAQ: ETSY)13.7% LOWER; reported Q2 revenue $528.9 million versus the consensus estimate of $524.84 million. Consolidated GMS was $3.0 billion, up 13.1% year-over-year; while Etsy marketplace GMS was $2.8 billion, up 14.2% year-over-year. Etsy sees Q3 2021 revenue of $500-525 million, versus the consensus of $524.91 million.\nPetIQ, Inc. (NASDAQ: PETQ)11.7% LOWER; reported Q2 EPS of $0.14, $0.59 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $271 million versus the consensus estimate of $304.72 million.\nLemonade (NYSE: LMND) 9.1% LOWER; reported Q2 EPS of ($0.90), $0.01 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $26.8 million. Lemonade sees Q3 2021 revenue of $32.5-33.5 million, versus the consensus of $32.32 million. Lemonade sees FY2021 revenue of $123-125 million, versus the consensus of $118.94 million.\nMaxar Technologies Ltd. (NYSE: MAXR)10.9% LOWER; reported Q2 EPS of $0.60, $0.46 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $473 million versus the consensus estimate of $560.3 million.\nRoku (NASDAQ: ROKU)8.4% LOWER; reported Q2 EPS of $0.52, $0.40 better than the analyst estimate of $0.12. Revenue for the quarter came in at $645.1 million versus the consensus estimate of $618.54 million. Roku sees Q3 2021 revenue of $675-685 million, versus the consensus of $645 million.\nWestern Union (NYSE: WU)6.2% HIGHER; Goldfinch and Baupost will acquire Western Union Business Solutions for approximately $910 million in cash. reported Q2 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.26 billion.\nMercadoLibre (NASDAQ: MELI)5.8% HIGHER; reported Q2 EPS of $1.37, $1.26 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.46 billion. Gross merchandise volume (“GMV”) grew to $7.0 billion, representing an increase of 39.2% in USD and 46.1% on an FX neutral basis.\nUber (NYSE: UBER)4.6% LOWER; reported Q2 EPS of $0.58, $1.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $3.93 billion versus the consensus estimate of $3.74 billion.\nElectronic Arts (NASDAQ: EA)3.5% HIGHER; reported Q1 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.28 billion.\nBooking Holdings (NASDAQ: BKNG)3.1% HIGHER; reported Q2 EPS of ($2.55), $0.45 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $1.9 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887119446,"gmtCreate":1632006704385,"gmtModify":1676530683652,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Ohhh","listText":"Ohhh","text":"Ohhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887119446","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890227802,"gmtCreate":1628121092106,"gmtModify":1703501474374,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890227802","repostId":"2157488120","repostType":4,"repost":{"id":"2157488120","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628119786,"share":"https://ttm.financial/m/news/2157488120?lang=&edition=fundamental","pubTime":"2021-08-05 07:29","market":"us","language":"en","title":"'Apex Legends' creator EA forecasts quarterly sales above estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2157488120","media":"Reuters","summary":"(Reuters) - Electronic Arts on Wednesday forecast current-quarter adjusted sales above estimates, as","content":"<p><img src=\"https://static.tigerbbs.com/1444bbd30f0bc939ee2d4a455a608627\" tg-width=\"200\" tg-height=\"133\" referrerpolicy=\"no-referrer\"></p>\n<p>(Reuters) -&nbsp;<a href=\"https://laohu8.com/S/EA\">Electronic Arts</a> on Wednesday forecast current-quarter adjusted sales above estimates, as the videogame maker bet on a strong performance from mainstay titles like \"FIFA 21\" and \"Apex Legends\", sending its shares up nearly 3% in extended trading.</p>\n<p>The Redwood City, California-based company also raised its annual sales forecast but that missed estimates, as easing COVID-19 curbs further into the year might slow down the lockdown-fueled gaming frenzy.</p>\n<p>Rivals <a href=\"https://laohu8.com/S/TTWO\">Take-Two</a> and <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> also forecast disappointing annual revenue earlier this week.</p>\n<p>Redwood City, California-based EA said it expects full-year adjusted sales of $7.40 billion versus $7.30 billion earlier, while analysts had estimated $7.45 billion, according to Refinitiv IBES data.</p>\n<p>It forecast second-quarter adjusted sales of $1.73 billion, exceeding expectations of $1.51 billion.</p>\n<p>EA had emerged as a clear pandemic winner after lockdowns ignited a boom in the time and money spent on games, driving an over 30% surge in the video game publisher's shares last year.</p>\n<p>But with rising vaccinations and easing restrictions in many countries, investors are now weighing if EA's big bet on mobile gaming will pay off as gamers leave their consoles behind to socialize outside.</p>\n<p>Backed by a strong balance sheet, EA has been on a buying spree worth billions of dollars to bolster its mobile gaming lineup, bringing Glu Mobile, UK-based Codemasters and Playdemic Ltd under its marquee since 2020.</p>\n<p>EA's adjusted sales stood at $1.34 billion for the first quarter ended June 30, beating expectations of $1.28 billion.</p>\n<p>Net income fell to $204 million, or 71 cents per share, from $365 million, or $1.25 per share, a year ago.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>'Apex Legends' creator EA forecasts quarterly sales above estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n'Apex Legends' creator EA forecasts quarterly sales above estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-05 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/1444bbd30f0bc939ee2d4a455a608627\" tg-width=\"200\" tg-height=\"133\" referrerpolicy=\"no-referrer\"></p>\n<p>(Reuters) -&nbsp;<a href=\"https://laohu8.com/S/EA\">Electronic Arts</a> on Wednesday forecast current-quarter adjusted sales above estimates, as the videogame maker bet on a strong performance from mainstay titles like \"FIFA 21\" and \"Apex Legends\", sending its shares up nearly 3% in extended trading.</p>\n<p>The Redwood City, California-based company also raised its annual sales forecast but that missed estimates, as easing COVID-19 curbs further into the year might slow down the lockdown-fueled gaming frenzy.</p>\n<p>Rivals <a href=\"https://laohu8.com/S/TTWO\">Take-Two</a> and <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> also forecast disappointing annual revenue earlier this week.</p>\n<p>Redwood City, California-based EA said it expects full-year adjusted sales of $7.40 billion versus $7.30 billion earlier, while analysts had estimated $7.45 billion, according to Refinitiv IBES data.</p>\n<p>It forecast second-quarter adjusted sales of $1.73 billion, exceeding expectations of $1.51 billion.</p>\n<p>EA had emerged as a clear pandemic winner after lockdowns ignited a boom in the time and money spent on games, driving an over 30% surge in the video game publisher's shares last year.</p>\n<p>But with rising vaccinations and easing restrictions in many countries, investors are now weighing if EA's big bet on mobile gaming will pay off as gamers leave their consoles behind to socialize outside.</p>\n<p>Backed by a strong balance sheet, EA has been on a buying spree worth billions of dollars to bolster its mobile gaming lineup, bringing Glu Mobile, UK-based Codemasters and Playdemic Ltd under its marquee since 2020.</p>\n<p>EA's adjusted sales stood at $1.34 billion for the first quarter ended June 30, beating expectations of $1.28 billion.</p>\n<p>Net income fell to $204 million, or 71 cents per share, from $365 million, or $1.25 per share, a year ago.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EA":"艺电"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157488120","content_text":"(Reuters) - Electronic Arts on Wednesday forecast current-quarter adjusted sales above estimates, as the videogame maker bet on a strong performance from mainstay titles like \"FIFA 21\" and \"Apex Legends\", sending its shares up nearly 3% in extended trading.\nThe Redwood City, California-based company also raised its annual sales forecast but that missed estimates, as easing COVID-19 curbs further into the year might slow down the lockdown-fueled gaming frenzy.\nRivals Take-Two and Activision Blizzard also forecast disappointing annual revenue earlier this week.\nRedwood City, California-based EA said it expects full-year adjusted sales of $7.40 billion versus $7.30 billion earlier, while analysts had estimated $7.45 billion, according to Refinitiv IBES data.\nIt forecast second-quarter adjusted sales of $1.73 billion, exceeding expectations of $1.51 billion.\nEA had emerged as a clear pandemic winner after lockdowns ignited a boom in the time and money spent on games, driving an over 30% surge in the video game publisher's shares last year.\nBut with rising vaccinations and easing restrictions in many countries, investors are now weighing if EA's big bet on mobile gaming will pay off as gamers leave their consoles behind to socialize outside.\nBacked by a strong balance sheet, EA has been on a buying spree worth billions of dollars to bolster its mobile gaming lineup, bringing Glu Mobile, UK-based Codemasters and Playdemic Ltd under its marquee since 2020.\nEA's adjusted sales stood at $1.34 billion for the first quarter ended June 30, beating expectations of $1.28 billion.\nNet income fell to $204 million, or 71 cents per share, from $365 million, or $1.25 per share, a year ago.","news_type":1},"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887119368,"gmtCreate":1632006597654,"gmtModify":1676530683628,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887119368","repostId":"1136416859","repostType":2,"repost":{"id":"1136416859","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631520337,"share":"https://ttm.financial/m/news/1136416859?lang=&edition=fundamental","pubTime":"2021-09-13 16:05","market":"us","language":"en","title":"Virgin Galactic stock dropped 3.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136416859","media":"Tiger Newspress","summary":"Virgin Galactic stock dropped 3.5% in premarket trading on delaying to space mission with Italian Ai","content":"<p>Virgin Galactic stock&nbsp;dropped 3.5% in premarket trading&nbsp;on&nbsp;delaying to space mission with Italian Air Force.</p>\n<p><img src=\"https://static.tigerbbs.com/65d1b70c4c67857a14c94c87b6cb9af9\" tg-width=\"892\" tg-height=\"821\" width=\"100%\" height=\"auto\"></p>\n<p>Virgin Galactic Holdings Inc&nbsp;on last&nbsp;Friday flagged a delay to its first commercial research mission with the Italian Air Force to mid-October due to a potential manufacturing defect.</p>\n<p>The company also attributed the delay in the mission, named \"Unity 23\", to the pending resolution of a probe by the U.S. Federal Aviation Administration (FAA).</p>\n<p>Virgin Galactic said on last&nbsp;Friday a third-party supplier warned of a potential manufacturing defect in a component of the flight control system during test flight preparations.</p>\n<p>\"At this point, it is not yet known whether the defect is present in the company's vehicles and what, if any, repair work may be needed,\" the company said, adding it was conducting inspections with the vendor.</p>\n<p>The mission was initially set for late September or early October to carry three paying crew members from the Italian Air Force and the Rome-based government agency National Research Council.</p>\n<p>The FAA is investigating the flight that took billionaire Richard Branson to space in July, and last week barred SpaceShipTwo flights until the agency approves the final mishap report or determines the issues do not affect public safety.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virgin Galactic stock dropped 3.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirgin Galactic stock dropped 3.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-13 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Virgin Galactic stock&nbsp;dropped 3.5% in premarket trading&nbsp;on&nbsp;delaying to space mission with Italian Air Force.</p>\n<p><img src=\"https://static.tigerbbs.com/65d1b70c4c67857a14c94c87b6cb9af9\" tg-width=\"892\" tg-height=\"821\" width=\"100%\" height=\"auto\"></p>\n<p>Virgin Galactic Holdings Inc&nbsp;on last&nbsp;Friday flagged a delay to its first commercial research mission with the Italian Air Force to mid-October due to a potential manufacturing defect.</p>\n<p>The company also attributed the delay in the mission, named \"Unity 23\", to the pending resolution of a probe by the U.S. Federal Aviation Administration (FAA).</p>\n<p>Virgin Galactic said on last&nbsp;Friday a third-party supplier warned of a potential manufacturing defect in a component of the flight control system during test flight preparations.</p>\n<p>\"At this point, it is not yet known whether the defect is present in the company's vehicles and what, if any, repair work may be needed,\" the company said, adding it was conducting inspections with the vendor.</p>\n<p>The mission was initially set for late September or early October to carry three paying crew members from the Italian Air Force and the Rome-based government agency National Research Council.</p>\n<p>The FAA is investigating the flight that took billionaire Richard Branson to space in July, and last week barred SpaceShipTwo flights until the agency approves the final mishap report or determines the issues do not affect public safety.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136416859","content_text":"Virgin Galactic stock dropped 3.5% in premarket trading on delaying to space mission with Italian Air Force.\n\nVirgin Galactic Holdings Inc on last Friday flagged a delay to its first commercial research mission with the Italian Air Force to mid-October due to a potential manufacturing defect.\nThe company also attributed the delay in the mission, named \"Unity 23\", to the pending resolution of a probe by the U.S. Federal Aviation Administration (FAA).\nVirgin Galactic said on last Friday a third-party supplier warned of a potential manufacturing defect in a component of the flight control system during test flight preparations.\n\"At this point, it is not yet known whether the defect is present in the company's vehicles and what, if any, repair work may be needed,\" the company said, adding it was conducting inspections with the vendor.\nThe mission was initially set for late September or early October to carry three paying crew members from the Italian Air Force and the Rome-based government agency National Research Council.\nThe FAA is investigating the flight that took billionaire Richard Branson to space in July, and last week barred SpaceShipTwo flights until the agency approves the final mishap report or determines the issues do not affect public safety.","news_type":1},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830707769,"gmtCreate":1629096328351,"gmtModify":1676529928257,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Wow does that mean the market is going down now?","listText":"Wow does that mean the market is going down now?","text":"Wow does that mean the market is going down now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/830707769","repostId":"895207908","repostType":1,"repost":{"id":895207908,"gmtCreate":1628744306004,"gmtModify":1676529840280,"author":{"id":"3568358014488959","authorId":"3568358014488959","name":"KennyLSJ","avatar":"https://static.tigerbbs.com/6b5ebe536d7e7f6f56f6fcaeab8f5eda","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3568358014488959","idStr":"3568358014488959"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities&nbsp;and user&nbsp;experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities&nbsp;and user&nbsp;experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","text":"$NIO Inc.(NIO)$I have been trading a lot on NIO since last year when they were on the edge of bankruptcy. And lucky enough, I followed them from $3/share to $52/share. In between there was a lot of selling and buyingback of the shares.I am amazed by the rate of growth for this young company that has just passed their 5 year mark not long ago.I see NIO not only as an EV company but more of a lifestyle. Their BaaS model together with NIOLife and NIOSpace has made them what they are today. Heavily focused on the customer service experience at their facilities and user experience of their end product. This has greatly assisted the company in their growth in both user acquisition and consumer loyalty.This is one company that I foresee a tremendou","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895207908","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263020299944016,"gmtCreate":1705248103136,"gmtModify":1705248107252,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Let's gooo!!! 2 more days!!","listText":"Let's gooo!!! 2 more days!!","text":"Let's gooo!!! 2 more days!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263020299944016","isVote":1,"tweetType":1,"viewCount":710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019712897248,"gmtCreate":1705247842474,"gmtModify":1705247847322,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Let's jeep it going! The end is near","listText":"Let's jeep it going! The end is near","text":"Let's jeep it going! The end is near","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019712897248","isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":262114045251600,"gmtCreate":1705027431924,"gmtModify":1705027436348,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"An easy way to learn and capitalise on the oppurtunity","listText":"An easy way to learn and capitalise on the oppurtunity","text":"An easy way to learn and capitalise on the oppurtunity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/262114045251600","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261879472197912,"gmtCreate":1704945782180,"gmtModify":1704945786601,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"A fun experience taking oart in thsi challenge","listText":"A fun experience taking oart in thsi challenge","text":"A fun experience taking oart in thsi challenge","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261879472197912","isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":268259076993168,"gmtCreate":1706510802436,"gmtModify":1706510810633,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$&nbsp;</a> have a good stronghold in the market&nbsp;","listText":"<a href=\"https://ttm.financial/S/MSFT\">$Microsoft(MSFT)$&nbsp;</a> have a good stronghold in the market&nbsp;","text":"$Microsoft(MSFT)$ have a good stronghold in the market","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/268259076993168","isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263164963803216,"gmtCreate":1705283421461,"gmtModify":1705283426272,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Think n tell me your views","listText":"Think n tell me your views","text":"Think n tell me your views","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263164963803216","isVote":1,"tweetType":1,"viewCount":546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019307909208,"gmtCreate":1705247884919,"gmtModify":1705247888950,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"huat all!","listText":"huat all!","text":"huat all!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019307909208","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":263019272527984,"gmtCreate":1705247860968,"gmtModify":1705247865266,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"That's the way&nbsp;","listText":"That's the way&nbsp;","text":"That's the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019272527984","repostId":"263019199787224","repostType":1,"repost":{"id":263019199787224,"gmtCreate":1705247703017,"gmtModify":1705247706445,"author":{"id":"3584008590338956","authorId":"3584008590338956","name":"Retire Smart","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584008590338956","idStr":"3584008590338956"},"themes":[],"htmlText":"Huat huat all the way","listText":"Huat huat all the way","text":"Huat huat all the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263019199787224","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":262455724106040,"gmtCreate":1705110155270,"gmtModify":1705110159916,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Come and enjoy free rewards","listText":"Come and enjoy free rewards","text":"Come and enjoy free rewards","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/262455724106040","isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261879256092832,"gmtCreate":1704945822447,"gmtModify":1704945826717,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Tiger revenue increasing as nyse charts a new high","listText":"Tiger revenue increasing as nyse charts a new high","text":"Tiger revenue increasing as nyse charts a new high","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261879256092832","isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261875544965352,"gmtCreate":1704944947207,"gmtModify":1704944950571,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261875544965352","repostId":"261578332447000","repostType":1,"repost":{"id":261578332447000,"gmtCreate":1704872261733,"gmtModify":1704872265634,"author":{"id":"3573162818118967","authorId":"3573162818118967","name":"Pepeflabs","avatar":"https://static.tigerbbs.com/bb2ce4a85b6af8ab6f45834a991797c6","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3573162818118967","idStr":"3573162818118967"},"themes":[],"htmlText":"Valod post vaild post","listText":"Valod post vaild post","text":"Valod post vaild post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261578332447000","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261875129536696,"gmtCreate":1704944841127,"gmtModify":1704944844913,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261875129536696","repostId":"261217496645664","repostType":1,"repost":{"id":261217496645664,"gmtCreate":1704801733495,"gmtModify":1705406662474,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/dc558bf32e48ad6ed6d057026ef55af7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667618821228","idStr":"3527667618821228"},"themes":[],"title":"Outperforming the Market by 140% in the Past Year: Is CRWD the Top Cybersecurity Stocks?","htmlText":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to <a href=\"https://ttm.financial/U/3586385042163137\">@Arshadrzk</a> for achieving a profit of over $1,000+ through the purchase of <a href=\"https://ttm.financial/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a> common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","listText":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the <a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$</a> by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to <a href=\"https://ttm.financial/U/3586385042163137\">@Arshadrzk</a> for achieving a profit of over $1,000+ through the purchase of <a href=\"https://ttm.financial/S/CRWD\">$CrowdStrike Holdings, Inc.(CRWD)$</a> common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","text":"How do you determine high-quality stocks? If outperforming the market is a criterion for identifying quality stocks, then this particular stock has exceeded expectations by surpassing the $NASDAQ(.IXIC)$ by 140%. Moreover, it is anticipated that this stock will continue to outperform the market throughout the first half of 2024.Curious about which stock this is? Let's find out!Congratulations to @Arshadrzk for achieving a profit of over $1,000+ through the purchase of $CrowdStrike Holdings, Inc.(CRWD)$ common stocks, with an outstanding return rate of 261.63%!👏👏👏 The cost price is only $67.61!!!My highest gain in my portfolio. Cybersecurity is essent","images":[{"img":"https://community-static.tradeup.com/news/2e55c5f5093e77e70ca0854e08a6be13","width":"1080","height":"1080"},{"img":"https://community-static.tradeup.com/news/a0307398b8a41055d8c9bb416c79f2a1","width":"1772","height":"771"},{"img":"https://community-static.tradeup.com/news/788ec0cd0e85522183278db2ff1ab0d3","width":"1440","height":"1080"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261217496645664","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":261591377039416,"gmtCreate":1704875428746,"gmtModify":1704875432099,"author":{"id":"3584711357780922","authorId":"3584711357780922","name":"Kathir","avatar":"https://static.tigerbbs.com/496cad753bfc1c79109f9876a085789c","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3584711357780922","idStr":"3584711357780922"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/261591377039416","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}